Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity-Reference-Cited by-同舟云学术

Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity

Published:2017-12 Issue: Volume:268 Page:92-101
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Wu Xiaoyan,Hu Zhenhua,Nizzero Sara,Zhang Guodong,Ramirez Maricela R.,Shi Ce,Zhou Jin,Ferrari Mauro,Shen Haifa

Funder

National Institute of Health

U.S. Department of Defense

Ernest Cockrell Jr. Distinguished Endowed Chair fund

Dottie and Jimmy C. Adair Myelodysplastic Syndrome Treatment and Research Funding

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference50 articles.

1. Myelodysplastic syndromes;Ades;Lancet,2014

2. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia;Cheson;Blood,2006

3. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML;Jiang;Blood,2009

4. Recent developments in myelodysplastic syndromes;Bejar;Blood,2014

5. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study;Welch;Am. J. Hematol.,2011

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone targeted nano-drug and nano-delivery;Bone Research;2024-09-04

2. Design of Nanodrug Delivery Systems for Tumor Bone Metastasis;Current Pharmaceutical Design;2024-04

3. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy;Cancer Communications;2024-02-04

4. The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis;Hematology;2023-10-31

5. Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer;Molecular Pharmaceutics;2023-10-30